What is PCAC and Why July 2026 Matters
The basics, plain English
The Pharmacy Compounding Advisory Committee (PCAC) is a federal advisory panel that advises the FDA on which bulk drug substances should appear on the official 503A Bulks List. When a substance is on that list, licensed 503A compounding pharmacies can prepare it for patient-specific prescriptions. When it's not on the list — and doesn't meet one of the other two exemptions — compounding is illegal.
This is not a theoretical concern. Between 2023 and 2024, the prior FDA moved 19 widely used peptides to Category 2 — a holding pen for substances deemed too risky for compounding. The practical effect was to shutter the compounding pathway for some of the most prescribed peptides in wellness and longevity medicine: BPC-157, TB-500, Semax, Epitalon, and others.
On April 15, 2026, the FDA updated the 503A Bulk Drug Substances list to remove 12 peptides from Category 2, citing withdrawn nominations. Simultaneously, it announced a two-day PCAC meeting on July 23–24, 2026, at the FDA White Oak Campus in Silver Spring, Maryland (virtual option available), to evaluate 7 of those peptides for formal inclusion on the 503A Bulks List.
Why this meeting sets rules for a decade
The 503A Bulks List final rulemaking process has been stalled for years. The PCAC is a required step — without its review and recommendation, the FDA cannot add these substances via notice-and-comment rulemaking without legal exposure. So the outcomes of this July meeting are the de facto determinant of what compounds are legally accessible for the foreseeable future.
This isn't a rubber stamp. PCAC has rejected peptides in prior meetings (2024), voting against inclusion for thymosin alpha-1 and others despite decades of clinical use. But the political environment has shifted. HHS Secretary Robert F. Kennedy Jr. has publicly stated he has used peptides with favorable results and supports broader access. The new PCAC membership is still being constituted — new appointments before July could change the outcome.
It is not an FDA drug approval proceeding. None of these peptides will become "FDA-approved drugs" as a result of this meeting.
It is not the final word. Even a favorable PCAC recommendation requires formal rulemaking before pharmacies can act.
It is not a license to compound today. Removal from Category 2 does not equal Category 1 status.
The most consequential regulatory milestone for peptide compounding in years.
A formal, public, vote-counted evaluation of whether these 7 substances can enter the lawful compounding pathway.
A signal of the FDA's intent for the next 3–5 years of enforcement.
The Substances at Risk
Used for gut healing, tendinopathy, and tissue repair. No FDA-approved drug contains BPC-157. Nominated for UC indication and wound healing. PCAC has reviewed it before. Public comment docket: FDA-2025-N-6895. Comment deadline July 9, 2026.
Anti-inflammatory tripeptide derived from alpha-MSH. Studied for dermatological conditions, inflammatory bowel disease, and neuroinflammation. Lower profile but no less contested than BPC-157.
Studied for muscle repair, flexibility, and cardiac function. Historically paired with BPC-157 in recovery protocols. The FDA's prior Category 2 designation was a significant disruption to sports medicine and integrative medicine practices.
Mitochondrial-encoded peptide studied for metabolic regulation, insulin sensitivity, and obesity. Originally identified in 2015; represents a newer class of metabolic peptides.
Studied for insomnia, anxiety, and stress management. Has a long history in European clinical use. Nominated for sleep and opioid withdrawal indications.
Nootropic and neuroprotective heptapeptide originally developed in Russia. Studied for cognitive enhancement, cerebral ischemia, and ADHD. High use in cognitive longevity circles.
Pineal gland-derived tetrapeptide studied for telomere length, circadian rhythm regulation, and anti-aging. One of the most widely used peptides in the longevity medicine community.
What's NOT on this agenda but is coming: Five additional peptides will be reviewed at a separate PCAC meeting before February 2027 — GHK-Cu (injectable), Melanotan II, Cathelicidin (LL-37), Dihexa Acetate, and Pegylated Mechano Growth Factor (PEG-MGF). Clinicians should monitor this second meeting as closely as the July session.
Separately and under a different proceeding, the FDA proposed in May 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely — finding "no clinical need" for bulk compounding of these substances by outsourcing facilities. The comment period closes June 30, 2026. If finalized, this closes the 503B compounding pathway for GLP-1s from bulk API. 503A pharmacies can still compound on patient-specific prescriptions, but the days of bulk-sourced compounded GLP-1s from 503B facilities are ending. This is a separate track from PCAC but equally consequential for clinics running GLP-1 protocols.
The 12-Month Clinic Playbook
Audit your current patient population by peptide
List every patient currently on a BPC-157, TB-500, Semax, Epitalon, MOTS-C, KPV, or DSIP protocol. Flag which ones are using peptides that were on Category 2 as of April 2026. Identify your current pharmacy source — 503A, 503B, or gray market.
Review and update intake forms
Add explicit fields for each of the 7 July PCAC peptides (not just semaglutide). Include a question: "Have you previously been on a peptide protocol? Which one? With which pharmacy?" Add a field documenting the pharmacy's 503A/503B status and COA on file.
Update contraindication screening checklists
Each peptide has different drug interaction profiles. At minimum, update for:
- BPC-157: anticoagulant interactions, GI surgery history
- Semax: ACE inhibitor interactions, cardiovascular history
- MOTS-C: diabetes medication interactions (Metformin, insulin)
- DSIP: CNS-active drug interactions (benzodiazepines, sleep aids)
Flag patients who need to be re-consented if they've been on protocols since before Category 2 was removed.
See it live → PeptidePilot's interactive screening demo shows exactly how contraindication rules trigger against patient profiles — updated automatically when FDA reclassifies a substance.
Get your 503A pharmacy relationships in writing
Contact your compounding pharmacy partners. Ask specifically:
- What is their FDA registration status (503A vs. 503B)?
- Are they tracking the July PCAC meeting?
- Do they have a protocol for reclassification events?
- Can they provide updated COA for each peptide batch?
Document these conversations in writing (email thread = record).
Submit a public comment to FDA-2025-N-6895 by July 9, 2026
This is the most direct, highest-leverage action a clinic can take. Comments must be filed at regulations.gov by July 9 to go directly to PCAC members. What to include: clinical experience data, patient outcomes, safety record, supply chain specifics. Keep it factual, not political — PCAC responds to clinical evidence.
Register for oral testimony if applicable
June 30 deadline to register for oral presentations at the July 23–24 meeting. If you have clinical data to present, this is worth the time investment. Contact your state medical society or the Pharmacy Compounding Foundation (APC offers resources) for support.
Document the PCAC vote outcomes for every peptide
Create an internal reference document listing each peptide, the PCAC vote (for/against/not reached), and the likely legal status change. Distribute to all prescribing clinicians and intake staff.
Update chart documentation standards
Every active patient chart should include:
- The specific peptide, dose, route, and indication documented
- A clinical rationale for the choice (not just "wellness" — be specific)
- The pharmacy's COA reference number
- Contraindication screening acknowledgment
- Consent form version and date
Review and update patient communication templates
Patients will ask: "Is my peptide still legal?" Have a templated response ready. For favorable reclassifications: explain what Category 1 status means, update pricing, confirm pharmacy relationship. For unfavorable outcomes: explain the timeline, suggest alternatives, provide a clear sunset date for the protocol.
Update intake forms again based on the November–December rulemaking
The FDA will initiate notice-and-comment rulemaking on any favorable PCAC recommendations. This process takes months. Monitor the Federal Register for any proposed rules. Update intake forms to reflect any interim enforcement discretion policies.
Audit your EMR / documentation system
Does your current system have structured fields for these peptides? Can you run a report of all patients currently on BPC-157, TB-500, Semax, etc.? If not, this is the time to address it — before the next regulatory event.
Establish a compliance monitoring protocol
Subscribe to FDA Federal Register updates for Docket FDA-2025-N-6895. Join the Alliance for Natural Health USA (anh-usa.org) — they cover PCAC proceedings closely. Set a quarterly calendar reminder to review the 503A Bulks List for changes. Designate a compliance point person in your clinic — even if it's one person with a checklist.
Compliance as a Living Service
How PeptidePilot Fits
Every reclassification event forces the same cycle — and most clinics are always behind
Every peptide added to or removed from the 503A Bulks List forces the same cycle across every clinic in the country: intake forms need updating, contraindication checklists need revising, charting templates need refreshing, patient communication needs to go out.
For most clinics, this cycle is manual and reactive. By the time the compliance update lands, weeks or months have passed. During that gap, patients are on outdated forms, contraindication screening doesn't account for the new reality, and clinicians are working from old chart documentation.
PeptidePilot is designed to eliminate that gap. When a peptide is reclassified — when it moves from Category 2 to Category 1, when a contraindication is updated, when a charting requirement changes — PeptidePilot's compliance infrastructure updates automatically. Intake forms reflect the current regulatory state. Contraindication checks pull from the latest evidence. Chart templates refresh with every classification event.
This isn't a feature added in response to PCAC. It's the architecture the platform was built around: compliance as a living service, not a one-time audit.
Free Briefing Series
Get PCAC Updates Before July 23
The FDA's July 2026 PCAC meeting will determine which peptides your clinic can legally compound — and which it cannot — for the next several years. PeptidePilot's regulatory team will send you concise, plain-English briefings as the meeting approaches and as decisions are made.
One email before the meeting. One after the vote. That's it. We don't sell your data.
Sources
- Federal Register Vol. 91, No. 73, April 16, 2026 (FDA-2025-N-6895)
- FDA 503A Bulk Drug Substances Categories Update, April 15, 2026 — fda.gov/media/94155/download
- FDA Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A, January 7, 2025
- FDA Federal Register Notice 2026-08552 (503B Bulks List — semaglutide/tirzepatide/liraglutide exclusion), May 1, 2026
- PCAC Meeting Calendar, July 23–24, 2026 — fda.gov/advisory-committees
- Frier Levitt, "FDA Removes 12 Popular Peptides from Category 2 'Do Not Compound' List," April 2026
- Lengea Law, "FDA Puts BPC-157, TB-500, and 5 Other Peptides Under the Microscope," April 16, 2026
- National Law Review, "FDA to Review Peptides for Addition to 503A Bulks List," April 2026
- Alliance for Natural Health USA, "FDA Signals Positive Shift on Peptides — But the Fight Is Far From Over," April 2026
- HealingMaps, "FDA to Review 7 Peptides for Compounding List in July 2026," April 2026